832-497-2220 [email protected]

Top-tier Chinese Pharmaceutical company profile: Harbin Pharmaceutical Group

Harbin Pharmaceutical Group Co., Ltd.

  • 2019 Revenue: US$ 17.33 Billion
  • Number of Employees: 20,000
  • Founded: 1971


Harbin Pharmaceutical Group Co., Ltd. (HPGC) is a China-based Sino-foreign equity joint venture, principally engaged in pharmaceutical manufacturing, trade, and R&D. The Company’s primary products include antibiotics, small-molecule drug preparations, OTC and healthcare products, modern Chinese medicines, biopharmaceuticals, and animal vaccines. The company distributes its products within domestic markets and to overseas markets.


HPGC has put resources accumulated from famous brands into technology innovation. Since 2011, HPGC has been in the process of setting up a new R&D location – HPGC Pharmaceutical Academy. The R&D institute has a full range of collaborations with domestic and international experts from prestigious universities and research institutes. Six research centers have already been established: research centers of small-molecule drugs, bioengineering drugs, drug preparation, modern Chinese medicines, OTC and healthcare products, and animal vaccines. The company has several innovative R&D platforms, such as a technology platform for extended, controlled, and immediate release drugs; a technology platform for fat emulsions, liposomes, and lipid microspheres; and technology platform for biopharmaceutical PEGylation. HPGC has over 140 new products. Its penicillin and cephalosporin C fermentation technologies are at a highly advanced level.

Products & Market

HPGC products are sold throughout China and have reached more than fifty countries in European, Asian, African, and Middle and North American markets. The company has 47 total registration approvals from 13 foreign countries. The market shares of its cephalosporin APIs and preparations, healthcare product series of calcium supplements, and injectable Chinese medicines consistently rank first in China.

Overseas investment

In 2018, HPGC reached a strategic partnership and joint venture agreement with GNC. HPGC invested $300 million in GNC, becoming the single largest shareholder. The two companies have agreed to form a joint venture for the manufacturing, marketing, sale, and distribution of GNC-branded products in China.

Other projects


Submit a Comment

Your email address will not be published.